The Relationship Between Optic Disc and Retinal Artery Position and Glaucomatous Visual Field Progression.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
02 09 2021
Historique:
entrez: 9 9 2021
pubmed: 10 9 2021
medline: 29 9 2021
Statut: ppublish

Résumé

To investigate whether retinal structural parameters, including positions of the optic disc and major retinal arteries, affect glaucomatous progression of the visual field (VF). In this cohort study, 116 eyes of 73 patients with primary open angle glaucoma (POAG) were included. VFs were measured using the Humphrey Field Analyzer 24-2 program and the VF was divided into seven sectors according to the corresponding optic disc angle. Average total deviation (TD) was calculated in each sector. Positions of major retinal arteries in the superotemporal and inferotemporal areas were decided by identifying the points where the retinal artery intersected the 3.4-mm-diameter circle around the optic disc. The relationship between sectorial TD VF progression rate and eight variables (age, mean and standard deviation of intraocular pressure during the observation period, baseline sectorial TD value, papillomacular bundle tilt angle, and axial length, along with superior/inferior arterial angle) was investigated. The main outcome measures were the association between retinal structural parameters and glaucomatous progression of VF. The superior retinal artery angular position was positively associated with sectorial TD progression rates in two central sectors in the inferior hemifield, which suggests faster VF progression where superior retinal artery angles are narrow. Papillomacular bundle tilt was not associated with TD progression rate in any sector. Progression of the inferior VF was associated with the superior retinal artery angular position in this study of POAG.

Identifiants

pubmed: 34499706
pii: 2777887
doi: 10.1167/iovs.62.12.6
pmc: PMC8434752
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6

Références

Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3152-8
pubmed: 27309619
Eur J Ophthalmol. 1992 Jan-Mar;2(1):33-5
pubmed: 1638164
Ophthalmology. 2011 Oct;118(10):1989-1994.e2
pubmed: 21684603
Arch Ophthalmol. 2011 May;129(5):562-8
pubmed: 21555607
Prog Retin Eye Res. 2013 Jan;32:1-21
pubmed: 22995953
Ophthalmology. 2016 Jul;123(7):1484-93
pubmed: 27157844
J Formos Med Assoc. 2008 Dec;107(12):952-7
pubmed: 19129056
Ophthalmology. 2007 Feb;114(2):216-20
pubmed: 17123613
Br J Ophthalmol. 2017 Dec;101(12):1658-1665
pubmed: 28450381
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
J Glaucoma. 2020 Oct;29(10):964-969
pubmed: 32618803
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
pubmed: 12049574
Ophthalmology. 2020 Jun;127(6):731-738
pubmed: 32081491
Invest Ophthalmol Vis Sci. 2015 Sep 1;56(10):6190-5
pubmed: 26416093
Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):407-417
pubmed: 29351357
Ophthalmologica. 1997;211(2):66-71
pubmed: 9097306
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5454-8
pubmed: 18055792
Ophthalmology. 2000 Oct;107(10):1809-15
pubmed: 11013178
Invest Ophthalmol Vis Sci. 2013 Aug 13;54(8):5481-8
pubmed: 23847316
Invest Ophthalmol Vis Sci. 2020 Sep 1;61(11):16
pubmed: 32915981
Am J Ophthalmol. 2017 Apr;176:53-60
pubmed: 28088508
J Glaucoma. 2017 Jan;26(1):34-40
pubmed: 27753756
Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2012-20
pubmed: 27127924
Sci Rep. 2020 Apr 20;10(1):6592
pubmed: 32313133
Acta Ophthalmol. 2013 Aug;91(5):406-12
pubmed: 23066646
Sci Rep. 2017 Mar 24;7(1):414
pubmed: 28341831
Ophthalmology. 2011 Oct;118(10):2050-7
pubmed: 21820741
Am J Ophthalmol. 1998 Oct;126(4):498-505
pubmed: 9780094
Jpn J Ophthalmol. 2017 Nov;61(6):441-447
pubmed: 28770355
Lancet. 2015 Apr 4;385(9975):1295-304
pubmed: 25533656
Sci Rep. 2019 Mar 5;9(1):3485
pubmed: 30837506
Control Clin Trials. 1994 Aug;15(4):299-325
pubmed: 7956270
Transl Vis Sci Technol. 2019 Aug 19;8(4):26
pubmed: 31440423
Invest Ophthalmol Vis Sci. 2012 Dec 19;53(13):8396-404
pubmed: 23154456
Am J Ophthalmol. 2016 Sep;169:33-45
pubmed: 27318077
Arch Ophthalmol. 2002 Oct;120(10):1268-79
pubmed: 12365904
PLoS One. 2018 Mar 15;13(3):e0193555
pubmed: 29543886

Auteurs

Yuri Fujino (Y)

Department of Ophthalmology, Seirei Hamamatsu General Hospital, Hamamatsu city, Shizuoka, Japan.
Department of Ophthalmology, Shimane University Faculty of Medicine, Matsue-shi, Shimane, Japan.

Ryo Asaoka (R)

Department of Ophthalmology, Seirei Hamamatsu General Hospital, Hamamatsu city, Shizuoka, Japan.
Seirei Christopher University, Hamamatsu city, Shizuoka, Japan.
Department of Ophthalmology, The University of Tokyo, Tokyo, Japan.
Nanovision Research Division, Research Institute of Electronics, Shizuoka University, Hamamatsu City, Shizuoka, Japan.
The Graduate School for the Creation of New Photonics Industries, Hamamatsu City, Shizuoka, Japan.

Hiroshi Murata (H)

Department of Ophthalmology, The University of Tokyo, Tokyo, Japan.

Takehiro Yamashita (T)

Department of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH